OBJECTIVES: To test prospectively the reproducibility and feasibility of endothelial pulse amplitude testing (Endo-PAT), a novel Food and Drug Administration-approved technology, in healthy adolescents. STUDY DESIGN: We performed Endo-PAT testing on 2 different days separated by no more than 7 days in 30 healthy fasting adolescents, ages 13 to 19 years, to assess reproducibility and feasibility. The reported level of discomfort, as measured on a pain scale of 1 to 5, was documented. RESULTS: The mean difference in paired Endo-PAT indices was 0.12 (95% CI, -0.09-0.33; P = .24; intraclass correlation coefficient, 0.78), and the within-subject variation of Endo-PAT index was 0.16. The Endo-PAT index on test days 1 and 2 were 1.91 +/- 0.57 and 1.78 +/- 0.51 (mean plus or minus SD), respectively. All attempted studies (100%) were completed (95% CI, 88%-100%), and all completed studies (100%) could be analyzed (95% CI, 88%-100%). The median pain score was 1 on both days. CONCLUSION: In healthy adolescents, Endo-PAT is feasible and has excellent reproducibility. This technology may provide an easy and reliable means of assessing endothelial function in the pediatric population.
OBJECTIVES: To test prospectively the reproducibility and feasibility of endothelial pulse amplitude testing (Endo-PAT), a novel Food and Drug Administration-approved technology, in healthy adolescents. STUDY DESIGN: We performed Endo-PAT testing on 2 different days separated by no more than 7 days in 30 healthy fasting adolescents, ages 13 to 19 years, to assess reproducibility and feasibility. The reported level of discomfort, as measured on a pain scale of 1 to 5, was documented. RESULTS: The mean difference in paired Endo-PAT indices was 0.12 (95% CI, -0.09-0.33; P = .24; intraclass correlation coefficient, 0.78), and the within-subject variation of Endo-PAT index was 0.16. The Endo-PAT index on test days 1 and 2 were 1.91 +/- 0.57 and 1.78 +/- 0.51 (mean plus or minus SD), respectively. All attempted studies (100%) were completed (95% CI, 88%-100%), and all completed studies (100%) could be analyzed (95% CI, 88%-100%). The median pain score was 1 on both days. CONCLUSION: In healthy adolescents, Endo-PAT is feasible and has excellent reproducibility. This technology may provide an easy and reliable means of assessing endothelial function in the pediatric population.
Authors: Aaron S Kelly; Andrea M Metzig; Kyle D Rudser; Angela K Fitch; Claudia K Fox; Brandon M Nathan; Mary M Deering; Betsy L Schwartz; M Jennifer Abuzzahab; Laura M Gandrud; Antoinette Moran; Charles J Billington; Sarah J Schwarzenberg Journal: Obesity (Silver Spring) Date: 2011-11-10 Impact factor: 5.002
Authors: Lisa C Hudgins; Vidhya Annavajjhala; Arzu Kovanlikaya; Maura D Frank; Aliza Solomon; Thomas S Parker; Rubin S Cooper Journal: Cardiol Young Date: 2015-05-05 Impact factor: 1.093
Authors: R J Widmer; M A Freund; A J Flammer; J Sexton; R Lennon; A Romani; N Mulinacci; F F Vinceri; L O Lerman; A Lerman Journal: Eur J Nutr Date: 2012-08-08 Impact factor: 5.614
Authors: Daniel Bulut; Michael Scheeler; Lisa Marie Niedballa; Thomas Miebach; Andreas Mügge Journal: Clin Res Cardiol Date: 2011-02-06 Impact factor: 5.460
Authors: Yasushi Matsuzawa; Sara Svedlund; Tatsuo Aoki; Raviteja R Guddeti; Taek-Geun Kwon; Rebecca Cilluffo; R Jay Widmer; Rebecca E Nelson; Ryan J Lennon; Lilach O Lerman; Sinsia Gao; Peter Ganz; Li-Ming Gan; Amir Lerman Journal: Int J Cardiol Date: 2015-04-16 Impact factor: 4.164